Exozymes Inc. (NASDAQ:EXOZ)
| Market Cap | $27.42M-81.3% |
| Revenue (ttm) | $0 |
| Net Income | -$10.14M-21.6% |
| EPS | -$1.17+4.1% |
| Shares Out | 9.44M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,823 |
| Open | $3.31 |
| Previous Close | $3.38 |
| Day's Range | $2.84 - $3.31 |
| 52-Week Range | $2.81 - $16.16 |
| Beta | 3.35 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 29, 2027 |
About EXOZ
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
Exozymes Inc. Stock Analysis — InsiderScore
Exozymes Inc. scored higher than 29% of companies evaluated by InsiderBuying, and ranked 62nd out of 107 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Exozymes Inc. bought $6.4K of stock across 5 purchases in the last 90 days, the largest of them $1.9K.
The average purchase added about 1% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 29, 2027Earnings report
$EXOZ stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in EXOZ holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by EXOZ's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
EXOZ Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New EXOZ patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to EXOZ from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in EXOZ
| VTIVanguard Morningstar Total Stock Market ETF | $281.16K |
| VXFVanguard Extended Market ETF | $92.27K |
| IWCiShares Micro-Cap ETF | $35.22K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from EXOZ’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 earnings with new Curia manufacturing deal and DOE grant announced; concrete business developments outweigh general update announcements.
Recent Insider Activity
Insider Score Trend Over Time
-13.3 since Sep 24Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
